Adverum Biotechnologies Inc (ADVM)
5.75
-0.42
(-6.81%)
USD |
NASDAQ |
Nov 21, 16:00
5.77
+0.02
(+0.35%)
Pre-Market: 20:00
Adverum Biotechnologies Enterprise Value: -33.63M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -33.63M |
| November 20, 2024 | -24.89M |
| November 19, 2024 | -23.23M |
| November 18, 2024 | -10.74M |
| November 15, 2024 | -10.54M |
| November 14, 2024 | -2.423M |
| November 13, 2024 | 4.026M |
| November 12, 2024 | 10.89M |
| November 11, 2024 | 8.186M |
| November 08, 2024 | 13.18M |
| November 07, 2024 | 11.10M |
| November 06, 2024 | 11.93M |
| November 05, 2024 | 7.354M |
| November 04, 2024 | 3.610M |
| November 01, 2024 | 0.9055M |
| October 31, 2024 | -1.487M |
| October 30, 2024 | 10.67M |
| October 29, 2024 | 8.174M |
| October 28, 2024 | 11.50M |
| October 25, 2024 | 12.75M |
| October 24, 2024 | 14.83M |
| October 23, 2024 | 15.66M |
| October 22, 2024 | 16.08M |
| October 21, 2024 | 18.57M |
| October 18, 2024 | 23.15M |
| Date | Value |
|---|---|
| October 17, 2024 | 14.83M |
| October 16, 2024 | 17.53M |
| October 15, 2024 | 6.718M |
| October 14, 2024 | 7.55M |
| October 11, 2024 | 5.886M |
| October 10, 2024 | 1.518M |
| October 09, 2024 | 3.182M |
| October 08, 2024 | 5.054M |
| October 07, 2024 | 1.518M |
| October 04, 2024 | 3.390M |
| October 03, 2024 | -1.810M |
| October 02, 2024 | -11.38M |
| October 01, 2024 | -16.16M |
| September 30, 2024 | -7.219M |
| September 27, 2024 | -29.47M |
| September 26, 2024 | -36.33M |
| September 25, 2024 | -36.75M |
| September 24, 2024 | -29.47M |
| September 23, 2024 | -30.72M |
| September 20, 2024 | -18.03M |
| September 19, 2024 | -17.82M |
| September 18, 2024 | -28.43M |
| September 17, 2024 | -21.98M |
| September 16, 2024 | -23.85M |
| September 13, 2024 | -23.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-191.08M
Minimum
May 16 2022
1.762B
Maximum
Jun 23 2020
192.33M
Average
-24.14M
Median
Nov 08 2023
Enterprise Value Benchmarks
| EyePoint Pharmaceuticals Inc | 316.10M |
| Cassava Sciences Inc | 1.399B |
| Regenxbio Inc | 199.36M |
| Editas Medicine Inc | -69.45M |
| Apellis Pharmaceuticals Inc | 3.507B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.13M |
| Revenue (Quarterly) | 1.00M |
| Total Expenses (Quarterly) | 30.22M |
| EPS Diluted (Quarterly) | -1.30 |
| Profit Margin (Quarterly) | -2.71K% |
| Earnings Yield | -104.5% |
| Normalized Earnings Yield | -104.52 |